TrialNature cardiovascular research2025

Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction.

Rahul Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.